Windtree Therapeutics Inc WINT
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.19
- Bid/Ask
- $0.01 / $0.02
- Shares Outstanding
- 33.71M
- Market Cap
- $33,708.78
- Volume/Avg
- 1,003 / 55,168
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.windtreetx.com
Valuation
|
Metric
|
WINT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
WINT
Financial Strength
|
Metric
|
WINT
|
|---|---|
Quick Ratio | 0.27 |
Current Ratio | 0.33 |
Interest Coverage | −90.13 |
Quick Ratio
WINT
Profitability
|
Metric
|
WINT
|
|---|---|
Return on Assets (Normalized) | −107.96% |
Return on Equity (Normalized) | −859.57% |
Return on Invested Capital (Normalized) | −333.19% |
Return on Assets
WINT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<SV<S! | LOCK|qSDmc | $128B | |||
| Moderna Inc
MRNA
| LOCK|zlJZQ& | LOCK|kG | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|h<#Wdmy | LOCK|FGnyV | $76B | |||
| argenx SE ADR
ARGX
| LOCK|^!kb<C | LOCK|j<P | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vJsvXV< | LOCK|@>g | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!^@sm<k | LOCK|c#Xv | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|LdyRrT@ | LOCK|LFq& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|R$^$?g | LOCK|m$$ | $23B | |||
| Incyte Corp
INCY
| LOCK|mHFY$> | LOCK|Z!r | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|gnb#f&T | LOCK|## | $14B |
United States